Skip to main content
Top
Published in: Respiratory Research 1/2023

Open Access 01-12-2023 | Computed Tomography | Research

Respiratory microbiota and radiomics features in the stable COPD patients

Authors: Rong Wang, Chunrong Huang, Wenjie Yang, Cui Wang, Ping Wang, Leixin Guo, Jin Cao, Lin Huang, Hejie Song, Chenhong Zhang, Yunhui Zhang, Guochao Shi

Published in: Respiratory Research | Issue 1/2023

Login to get access

Abstract

Backgrounds

The respiratory microbiota and radiomics correlate with the disease severity and prognosis of chronic obstructive pulmonary disease (COPD). We aim to characterize the respiratory microbiota and radiomics features of COPD patients and explore the relationship between them.

Methods

Sputa from stable COPD patients were collected for bacterial 16 S rRNA gene sequencing and fungal Internal Transcribed Spacer (ITS) sequencing. Chest computed tomography (CT) and 3D-CT analysis were conducted for radiomics information, including the percentages of low attenuation area below − 950 Hounsfield Units (LAA%), wall thickness (WT), and intraluminal area (Ai). WT and Ai were adjusted by body surface area (BSA) to WT/\(\sqrt{\text{B}\text{S}\text{A}}\) and Ai/BSA, respectively. Some key pulmonary function indicators were collected, which included forced expiratory volume in one second (FEV1), forced vital capacity (FVC), diffusion lung carbon monoxide (DLco). Differences and correlations of microbiomics with radiomics and clinical indicators between different patient subgroups were assessed.

Results

Two bacterial clusters dominated by Streptococcus and Rothia were identified. Chao and Shannon indices were higher in the Streptococcus cluster than that in the Rothia cluster. Principal Co-ordinates Analysis (PCoA) indicated significant differences between their community structures. Higher relative abundance of Actinobacteria was detected in the Rothia cluster. Some genera were more common in the Streptococcus cluster, mainly including Leptotrichia, Oribacterium, Peptostreptococcus. Peptostreptococcus was positively correlated with DLco per unit of alveolar volume as a percentage of predicted value (DLco/VA%pred). The patients with past-year exacerbations were more in the Streptococcus cluster. Fungal analysis revealed two clusters dominated by Aspergillus and Candida. Chao and Shannon indices of the Aspergillus cluster were higher than that in the Candida cluster. PCoA showed distinct community compositions between the two clusters. Greater abundance of Cladosporium and Penicillium was found in the Aspergillus cluster. The patients of the Candida cluster had upper FEV1 and FEV1/FVC levels. In radiomics, the patients of the Rothia cluster had higher LAA% and WT/\(\sqrt{\text{B}\text{S}\text{A}}\) than those of the Streptococcus cluster. Haemophilus, Neisseria and Cutaneotrichosporon positively correlated with Ai/BSA, but Cladosporium negatively correlated with Ai/BSA.

Conclusions

Among respiratory microbiota in stable COPD patients, Streptococcus dominance was associated with an increased risk of exacerbation, and Rothia dominance was relevant to worse emphysema and airway lesions. Peptostreptococcus, Haemophilus, Neisseria and Cutaneotrichosporon probably affected COPD progression and potentially could be disease prediction biomarkers.
Appendix
Available only for authorised users
Literature
1.
go back to reference Rabe K F, Halpin D M G, Han M K, et al. Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial [J]. Respiratory research, 2020, 21(1): 177–177.PubMedPubMedCentralCrossRef Rabe K F, Halpin D M G, Han M K, et al. Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial [J]. Respiratory research, 2020, 21(1): 177–177.PubMedPubMedCentralCrossRef
2.
go back to reference Li M, Cheng K, Ku K, et al. Factors influencing the length of Hospital Stay among Patients with Chronic Obstructive Pulmonary Disease (COPD) in Macao Population: a retrospective study of Inpatient Health record [J]. Int J Chron Obstruct Pulmon Dis, 2021, 16: 1677–1685.PubMedPubMedCentralCrossRef Li M, Cheng K, Ku K, et al. Factors influencing the length of Hospital Stay among Patients with Chronic Obstructive Pulmonary Disease (COPD) in Macao Population: a retrospective study of Inpatient Health record [J]. Int J Chron Obstruct Pulmon Dis, 2021, 16: 1677–1685.PubMedPubMedCentralCrossRef
3.
go back to reference Yoon C M, Nam M, Oh Y M, et al. Mitochondrial regulation of Inflammasome Activation in Chronic Obstructive Pulmonary Disease [J]. J Innate Immun, 2016, 8(2): 121–128.PubMedCrossRef Yoon C M, Nam M, Oh Y M, et al. Mitochondrial regulation of Inflammasome Activation in Chronic Obstructive Pulmonary Disease [J]. J Innate Immun, 2016, 8(2): 121–128.PubMedCrossRef
4.
go back to reference World Health O. World health statistics 2021: monitoring health for the SDGs, sustainable development goals [M]. Geneva: World Health Organization, 2021. World Health O. World health statistics 2021: monitoring health for the SDGs, sustainable development goals [M]. Geneva: World Health Organization, 2021.
5.
go back to reference Chotirmall S H, Gellatly S L, Budden K F, et al. Microbiomes in respiratory health and disease: An Asia-Pacific perspective [J]. Respirology (Carlton, Vic), 2017, 22(2): 240–250. Chotirmall S H, Gellatly S L, Budden K F, et al. Microbiomes in respiratory health and disease: An Asia-Pacific perspective [J]. Respirology (Carlton, Vic), 2017, 22(2): 240–250.
7.
go back to reference Rogers G B, Wesselingh S. Precision respiratory medicine and the microbiome [J]. The Lancet Respiratory Medicine, 2016, 4(1): 73–82.PubMedCrossRef Rogers G B, Wesselingh S. Precision respiratory medicine and the microbiome [J]. The Lancet Respiratory Medicine, 2016, 4(1): 73–82.PubMedCrossRef
8.
go back to reference Wypych T P, Wickramasinghe L C, Marsland B J. The influence of the microbiome on respiratory health [J]. Nat Immunol, 2019, 20(10): 1279–1290.PubMedCrossRef Wypych T P, Wickramasinghe L C, Marsland B J. The influence of the microbiome on respiratory health [J]. Nat Immunol, 2019, 20(10): 1279–1290.PubMedCrossRef
9.
go back to reference Budden K F, Shukla S D, Rehman S F, et al. Functional effects of the microbiota in chronic respiratory disease [J]. The Lancet Respiratory Medicine, 2019, 7(10): 907–920.PubMedCrossRef Budden K F, Shukla S D, Rehman S F, et al. Functional effects of the microbiota in chronic respiratory disease [J]. The Lancet Respiratory Medicine, 2019, 7(10): 907–920.PubMedCrossRef
10.
go back to reference Dicker A J, Huang J T J, Lonergan M, et al. The sputum microbiome, airway inflammation, and mortality in chronic obstructive pulmonary disease [J]. J Allergy Clin Immunol, 2021, 147(1): 158–167.PubMedCrossRef Dicker A J, Huang J T J, Lonergan M, et al. The sputum microbiome, airway inflammation, and mortality in chronic obstructive pulmonary disease [J]. J Allergy Clin Immunol, 2021, 147(1): 158–167.PubMedCrossRef
11.
go back to reference Yang C Y, Li S W, Chin C Y, et al. Association of exacerbation phenotype with the sputum microbiome in chronic obstructive pulmonary disease patients during the clinically stable state [J]. J Transl Med, 2021, 19(1): 121.PubMedPubMedCentralCrossRef Yang C Y, Li S W, Chin C Y, et al. Association of exacerbation phenotype with the sputum microbiome in chronic obstructive pulmonary disease patients during the clinically stable state [J]. J Transl Med, 2021, 19(1): 121.PubMedPubMedCentralCrossRef
12.
go back to reference Gillies R J, Kinahan P E, Hricak H. Radiomics: images are more than pictures, They Are Data [J]. Radiology, 2016, 278(2): 563–577.PubMed Gillies R J, Kinahan P E, Hricak H. Radiomics: images are more than pictures, They Are Data [J]. Radiology, 2016, 278(2): 563–577.PubMed
13.
go back to reference Lambin P, Rios-Velazquez E, Leijenaar R, et al. Radiomics: extracting more information from medical images using advanced feature analysis [J]. European Journal of Cancer (Oxford, England: 1990), 2012, 48(4): 441–446. Lambin P, Rios-Velazquez E, Leijenaar R, et al. Radiomics: extracting more information from medical images using advanced feature analysis [J]. European Journal of Cancer (Oxford, England: 1990), 2012, 48(4): 441–446.
15.
go back to reference Muller N L, Staples C A, Miller R R, et al. “Density mask”. An objective method to quantitate emphysema using computed tomography [J]. Chest, 1988, 94(4): 782–787.PubMed Muller N L, Staples C A, Miller R R, et al. “Density mask”. An objective method to quantitate emphysema using computed tomography [J]. Chest, 1988, 94(4): 782–787.PubMed
16.
go back to reference Tanabe N, Sato S, Oguma T, et al. Associations of airway tree to lung volume ratio on computed tomography with lung function and symptoms in chronic obstructive pulmonary disease [J]. Respir Res, 2019, 20(1): 77.PubMedPubMedCentralCrossRef Tanabe N, Sato S, Oguma T, et al. Associations of airway tree to lung volume ratio on computed tomography with lung function and symptoms in chronic obstructive pulmonary disease [J]. Respir Res, 2019, 20(1): 77.PubMedPubMedCentralCrossRef
17.
go back to reference Pompe E, Strand M, Van Rikxoort E M, et al. Five-year Progression of Emphysema and Air Trapping at CT in smokers with and those without Chronic Obstructive Pulmonary Disease: results from the COPDGene study [J]. Radiology, 2020, 295(1): 218–226.PubMedCrossRef Pompe E, Strand M, Van Rikxoort E M, et al. Five-year Progression of Emphysema and Air Trapping at CT in smokers with and those without Chronic Obstructive Pulmonary Disease: results from the COPDGene study [J]. Radiology, 2020, 295(1): 218–226.PubMedCrossRef
18.
go back to reference Konietzke P, Wielputz M O, Wagner W L, et al. Quantitative CT detects progression in COPD patients with severe emphysema in a 3-month interval [J]. Eur Radiol, 2020, 30(5): 2502–2512.PubMedCrossRef Konietzke P, Wielputz M O, Wagner W L, et al. Quantitative CT detects progression in COPD patients with severe emphysema in a 3-month interval [J]. Eur Radiol, 2020, 30(5): 2502–2512.PubMedCrossRef
19.
go back to reference Tanabe N, Sato S, Tanimura K, et al. Associations of CT evaluations of antigravity muscles, emphysema and airway disease with longitudinal outcomes in patients with COPD [J]. Thorax, 2021, 76(3): 295–297.PubMedCrossRef Tanabe N, Sato S, Tanimura K, et al. Associations of CT evaluations of antigravity muscles, emphysema and airway disease with longitudinal outcomes in patients with COPD [J]. Thorax, 2021, 76(3): 295–297.PubMedCrossRef
20.
go back to reference Lim J U, Kim E K, Lim S Y, et al. Mixed phenotype of Emphysema and Airway Wall Thickening is Associated with frequent exacerbation in Chronic Obstructive Pulmonary Disease patients [J]. Int J Chron Obstruct Pulmon Dis, 2019, 14: 3035–3042.PubMedPubMedCentralCrossRef Lim J U, Kim E K, Lim S Y, et al. Mixed phenotype of Emphysema and Airway Wall Thickening is Associated with frequent exacerbation in Chronic Obstructive Pulmonary Disease patients [J]. Int J Chron Obstruct Pulmon Dis, 2019, 14: 3035–3042.PubMedPubMedCentralCrossRef
21.
go back to reference Bodduluri S, Kizhakke Puliyakote A, Nakhmani A, et al. Computed tomography-based Airway Surface Area-to-volume ratio for phenotyping Airway Remodeling in Chronic Obstructive Pulmonary Disease [J]. American Journal of Respiratory and Critical Care Medicine, 2021, 203(2): 185–191.PubMedPubMedCentralCrossRef Bodduluri S, Kizhakke Puliyakote A, Nakhmani A, et al. Computed tomography-based Airway Surface Area-to-volume ratio for phenotyping Airway Remodeling in Chronic Obstructive Pulmonary Disease [J]. American Journal of Respiratory and Critical Care Medicine, 2021, 203(2): 185–191.PubMedPubMedCentralCrossRef
22.
go back to reference Wedzicha J A, Seemungal T A R. COPD exacerbations: defining their cause and prevention [J]. The Lancet, 2007, 370(9589): 786–796.CrossRef Wedzicha J A, Seemungal T A R. COPD exacerbations: defining their cause and prevention [J]. The Lancet, 2007, 370(9589): 786–796.CrossRef
23.
go back to reference Seemungal T A, Donaldson G C, Paul E A, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease [J]. American Journal of Respiratory and Critical Care Medicine, 1998, 157(5 Pt 1): 1418–1422.PubMedCrossRef Seemungal T A, Donaldson G C, Paul E A, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease [J]. American Journal of Respiratory and Critical Care Medicine, 1998, 157(5 Pt 1): 1418–1422.PubMedCrossRef
24.
go back to reference Miller M R, Hankinson J, Brusasco V, et al. Standardisation of spirometry [J]. Eur Respir J, 2005, 26(2): 319–338.PubMedCrossRef Miller M R, Hankinson J, Brusasco V, et al. Standardisation of spirometry [J]. Eur Respir J, 2005, 26(2): 319–338.PubMedCrossRef
25.
go back to reference Callahan B J, Mcmurdie P J, Rosen M J, et al. DADA2: high-resolution sample inference from Illumina amplicon data [J]. Nat Methods, 2016, 13(7): 581–583.PubMedPubMedCentralCrossRef Callahan B J, Mcmurdie P J, Rosen M J, et al. DADA2: high-resolution sample inference from Illumina amplicon data [J]. Nat Methods, 2016, 13(7): 581–583.PubMedPubMedCentralCrossRef
26.
go back to reference Falony G, Joossens M, Vieira-Silva S, et al. Population-level analysis of gut microbiome variation [J]. Science (New York, NY), 2016, 352(6285): 560–564. Falony G, Joossens M, Vieira-Silva S, et al. Population-level analysis of gut microbiome variation [J]. Science (New York, NY), 2016, 352(6285): 560–564.
27.
go back to reference Costea P I, Hildebrand F, Arumugam M, et al. Enterotypes in the landscape of gut microbial community composition [J]. Nat Microbiol, 2018, 3(1): 8–16.PubMedCrossRef Costea P I, Hildebrand F, Arumugam M, et al. Enterotypes in the landscape of gut microbial community composition [J]. Nat Microbiol, 2018, 3(1): 8–16.PubMedCrossRef
28.
go back to reference Karayama M, Inui N, Yasui H, et al. Physiological and morphological differences of airways between COPD and asthma-COPD overlap [J]. Sci Rep, 2019, 9(1): 7818.PubMedPubMedCentralCrossRef Karayama M, Inui N, Yasui H, et al. Physiological and morphological differences of airways between COPD and asthma-COPD overlap [J]. Sci Rep, 2019, 9(1): 7818.PubMedPubMedCentralCrossRef
29.
go back to reference Karayama M, Inui N, Mori K, et al. Respiratory impedance is correlated with airway narrowing in asthma using three-dimensional computed tomography [J]. Clin Exp Allergy, 2018, 48(3): 278–287.PubMedCrossRef Karayama M, Inui N, Mori K, et al. Respiratory impedance is correlated with airway narrowing in asthma using three-dimensional computed tomography [J]. Clin Exp Allergy, 2018, 48(3): 278–287.PubMedCrossRef
30.
go back to reference Karayama M, Inui N, Mori K, et al. Respiratory impedance is correlated with morphological changes in the lungs on three-dimensional CT in patients with COPD [J]. Sci Rep, 2017, 7: 41709.PubMedPubMedCentralCrossRef Karayama M, Inui N, Mori K, et al. Respiratory impedance is correlated with morphological changes in the lungs on three-dimensional CT in patients with COPD [J]. Sci Rep, 2017, 7: 41709.PubMedPubMedCentralCrossRef
31.
go back to reference Wang Z, Locantore N, Haldar K, et al. Inflammatory endotype-associated Airway Microbiome in Chronic Obstructive Pulmonary Disease Clinical Stability and Exacerbations: a Multicohort Longitudinal analysis [J]. American journal of respiratory and critical care medicine, 2021, 203(12): 1488–1502.PubMedPubMedCentralCrossRef Wang Z, Locantore N, Haldar K, et al. Inflammatory endotype-associated Airway Microbiome in Chronic Obstructive Pulmonary Disease Clinical Stability and Exacerbations: a Multicohort Longitudinal analysis [J]. American journal of respiratory and critical care medicine, 2021, 203(12): 1488–1502.PubMedPubMedCentralCrossRef
32.
go back to reference Wang Z, Bafadhel M, Haldar K, et al. Lung microbiome dynamics in COPD exacerbations [J]. Eur Respir J, 2016, 47(4): 1082–1092.PubMedCrossRef Wang Z, Bafadhel M, Haldar K, et al. Lung microbiome dynamics in COPD exacerbations [J]. Eur Respir J, 2016, 47(4): 1082–1092.PubMedCrossRef
33.
go back to reference Dickson R P, Martinez F J, Huffnagle G B. The role of the microbiome in exacerbations of chronic lung diseases [J]. The Lancet, 2014, 384(9944): 691–702.CrossRef Dickson R P, Martinez F J, Huffnagle G B. The role of the microbiome in exacerbations of chronic lung diseases [J]. The Lancet, 2014, 384(9944): 691–702.CrossRef
34.
go back to reference Ren L, Zhang R, Rao J, et al. Transcriptionally active lung Microbiome and its Association with bacterial biomass and host inflammatory status [J]. mSystems, 2018, 3(5). Ren L, Zhang R, Rao J, et al. Transcriptionally active lung Microbiome and its Association with bacterial biomass and host inflammatory status [J]. mSystems, 2018, 3(5).
35.
go back to reference Zhang X, Zheng H, Zhang H, et al. Increased interleukin (IL)-8 and decreased IL-17 production in chronic obstructive pulmonary disease (COPD) provoked by cigarette smoke [J]. Cytokine, 2011, 56(3): 717–725.PubMedCrossRef Zhang X, Zheng H, Zhang H, et al. Increased interleukin (IL)-8 and decreased IL-17 production in chronic obstructive pulmonary disease (COPD) provoked by cigarette smoke [J]. Cytokine, 2011, 56(3): 717–725.PubMedCrossRef
36.
go back to reference Bhowmik A, Seemungal T A, Sapsford R J, et al. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations [J]. Thorax, 2000, 55(2): 114–120.PubMedPubMedCentralCrossRef Bhowmik A, Seemungal T A, Sapsford R J, et al. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations [J]. Thorax, 2000, 55(2): 114–120.PubMedPubMedCentralCrossRef
37.
go back to reference Berenson C S, Kruzel R L, Eberhardt E, et al. Impaired innate immune alveolar macrophage response and the predilection for COPD exacerbations [J]. Thorax, 2014, 69(9): 811–818.PubMedCrossRef Berenson C S, Kruzel R L, Eberhardt E, et al. Impaired innate immune alveolar macrophage response and the predilection for COPD exacerbations [J]. Thorax, 2014, 69(9): 811–818.PubMedCrossRef
38.
go back to reference Liu H, Zheng D, Lin Y, et al. Association of sputum microbiome with clinical outcome of initial antibiotic treatment in hospitalized patients with acute exacerbations of COPD [J]. Pharmacol Res, 2020, 160: 105095.PubMedCrossRef Liu H, Zheng D, Lin Y, et al. Association of sputum microbiome with clinical outcome of initial antibiotic treatment in hospitalized patients with acute exacerbations of COPD [J]. Pharmacol Res, 2020, 160: 105095.PubMedCrossRef
39.
go back to reference Wikoff W R, Anfora A T, Liu J, et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites [J]. Proc Natl Acad Sci U S A, 2009, 106(10): 3698–3703.PubMedPubMedCentralCrossRef Wikoff W R, Anfora A T, Liu J, et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites [J]. Proc Natl Acad Sci U S A, 2009, 106(10): 3698–3703.PubMedPubMedCentralCrossRef
40.
go back to reference Wlodarska M, Luo C, Kolde R, et al. Indoleacrylic Acid produced by Commensal Peptostreptococcus Species suppresses inflammation [J]. Cell Host Microbe, 2017, 22(1): 25–37 e26.PubMedPubMedCentralCrossRef Wlodarska M, Luo C, Kolde R, et al. Indoleacrylic Acid produced by Commensal Peptostreptococcus Species suppresses inflammation [J]. Cell Host Microbe, 2017, 22(1): 25–37 e26.PubMedPubMedCentralCrossRef
41.
go back to reference Long X, Wong C C, Tong L, et al. Peptostreptococcus anaerobius promotes colorectal carcinogenesis and modulates tumour immunity [J]. Nature Microbiology, 2019, 4(12): 2319–2330.PubMedCrossRef Long X, Wong C C, Tong L, et al. Peptostreptococcus anaerobius promotes colorectal carcinogenesis and modulates tumour immunity [J]. Nature Microbiology, 2019, 4(12): 2319–2330.PubMedCrossRef
42.
go back to reference Tsoi H, Chu E S H, Zhang X, et al. Peptostreptococcus anaerobius induces intracellular cholesterol biosynthesis in Colon cells to Induce Proliferation and causes dysplasia in mice [J]. Gastroenterology, 2017, 152(6). Tsoi H, Chu E S H, Zhang X, et al. Peptostreptococcus anaerobius induces intracellular cholesterol biosynthesis in Colon cells to Induce Proliferation and causes dysplasia in mice [J]. Gastroenterology, 2017, 152(6).
43.
go back to reference Vernocchi P, Gili T, Conte F, et al. Network Analysis of Gut Microbiome and Metabolome to Discover Microbiota-Linked biomarkers in patients affected by Non-Small Cell Lung Cancer [J]. Int J Mol Sci, 2020, 21(22). Vernocchi P, Gili T, Conte F, et al. Network Analysis of Gut Microbiome and Metabolome to Discover Microbiota-Linked biomarkers in patients affected by Non-Small Cell Lung Cancer [J]. Int J Mol Sci, 2020, 21(22).
44.
go back to reference Tiew P Y, Mac Aogain M, Ali N a T B M, et al. The Mycobiome in Health and Disease: emerging concepts, Methodologies and Challenges [J]. Mycopathologia, 2020, 185(2): 207–231.PubMedPubMedCentral Tiew P Y, Mac Aogain M, Ali N a T B M, et al. The Mycobiome in Health and Disease: emerging concepts, Methodologies and Challenges [J]. Mycopathologia, 2020, 185(2): 207–231.PubMedPubMedCentral
45.
go back to reference Ali N A, Mac Aogáin M, Morales R F, et al. Optimisation and benchmarking of targeted amplicon sequencing for Mycobiome Analysis of respiratory specimens [J/OL] 2019, 20(20). Ali N A, Mac Aogáin M, Morales R F, et al. Optimisation and benchmarking of targeted amplicon sequencing for Mycobiome Analysis of respiratory specimens [J/OL] 2019, 20(20).
46.
go back to reference Bafadhel M, Mckenna S, Agbetile J, et al. Aspergillus fumigatus during stable state and exacerbations of COPD [J]. Eur Respir J, 2014, 43(1): 64–71.PubMedCrossRef Bafadhel M, Mckenna S, Agbetile J, et al. Aspergillus fumigatus during stable state and exacerbations of COPD [J]. Eur Respir J, 2014, 43(1): 64–71.PubMedCrossRef
47.
go back to reference Tiew P Y, Dicker A J, Keir H R, et al. A high-risk airway mycobiome is associated with frequent exacerbation and mortality in COPD [J]. Eur Respir J, 2021, 57(3). Tiew P Y, Dicker A J, Keir H R, et al. A high-risk airway mycobiome is associated with frequent exacerbation and mortality in COPD [J]. Eur Respir J, 2021, 57(3).
48.
go back to reference Tiew P Y, Narayana J K, Li Quek M S, et al. Sensitisation to recombinant aspergillus fumigatus allergens and clinical outcomes in COPD [J]. Eur Respir J, 2022. Tiew P Y, Narayana J K, Li Quek M S, et al. Sensitisation to recombinant aspergillus fumigatus allergens and clinical outcomes in COPD [J]. Eur Respir J, 2022.
49.
go back to reference Bulpa P, Dive A, Sibille Y. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease [J]. Eur Respir J, 2007, 30(4): 782–800.PubMedCrossRef Bulpa P, Dive A, Sibille Y. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease [J]. Eur Respir J, 2007, 30(4): 782–800.PubMedCrossRef
50.
go back to reference Kosmidis C, Denning D W. The clinical spectrum of pulmonary aspergillosis [J]. Thorax, 2015, 70(3): 270–277.PubMedCrossRef Kosmidis C, Denning D W. The clinical spectrum of pulmonary aspergillosis [J]. Thorax, 2015, 70(3): 270–277.PubMedCrossRef
51.
go back to reference Tiew P Y, Ko F W S, Pang S L, et al. Environmental fungal sensitisation associates with poorer clinical outcomes in COPD [J]. Eur Respir J, 2020, 56(2). Tiew P Y, Ko F W S, Pang S L, et al. Environmental fungal sensitisation associates with poorer clinical outcomes in COPD [J]. Eur Respir J, 2020, 56(2).
52.
go back to reference Zuo Y H, Wang W Q, Chen Q J, et al. Candida in Lower Respiratory Tract increases the frequency of Acute Exacerbation of Chronic Obstructive Pulmonary Disease: a retrospective case-control study [J]. Front Cell Infect Microbiol, 2020, 10: 538005.PubMedPubMedCentralCrossRef Zuo Y H, Wang W Q, Chen Q J, et al. Candida in Lower Respiratory Tract increases the frequency of Acute Exacerbation of Chronic Obstructive Pulmonary Disease: a retrospective case-control study [J]. Front Cell Infect Microbiol, 2020, 10: 538005.PubMedPubMedCentralCrossRef
53.
go back to reference Waatevik M, Frisk B, Real F G, et al. CT-defined emphysema in COPD patients and risk for change in desaturation status in 6-min walk test [J]. Respir Med, 2021, 187: 106542.PubMedCrossRef Waatevik M, Frisk B, Real F G, et al. CT-defined emphysema in COPD patients and risk for change in desaturation status in 6-min walk test [J]. Respir Med, 2021, 187: 106542.PubMedCrossRef
54.
go back to reference Yun J, Cho Y H, Lee S M, et al. Deep radiomics-based survival prediction in patients with chronic obstructive pulmonary disease [J]. Sci Rep, 2021, 11(1): 15144.PubMedPubMedCentralCrossRef Yun J, Cho Y H, Lee S M, et al. Deep radiomics-based survival prediction in patients with chronic obstructive pulmonary disease [J]. Sci Rep, 2021, 11(1): 15144.PubMedPubMedCentralCrossRef
55.
go back to reference Gonzalez G, Ash S Y, Vegas-Sanchez-Ferrero G, et al. Disease staging and prognosis in smokers using deep learning in chest computed tomography [J]. Am J Respir Crit Care Med, 2018, 197(2): 193–203.PubMedPubMedCentralCrossRef Gonzalez G, Ash S Y, Vegas-Sanchez-Ferrero G, et al. Disease staging and prognosis in smokers using deep learning in chest computed tomography [J]. Am J Respir Crit Care Med, 2018, 197(2): 193–203.PubMedPubMedCentralCrossRef
56.
go back to reference Engel M, Endesfelder D, Schloter-Hai B, et al. Influence of lung CT changes in chronic obstructive pulmonary disease (COPD) on the human lung microbiome [J]. PLoS One, 2017, 12(7): e0180859.PubMedPubMedCentralCrossRef Engel M, Endesfelder D, Schloter-Hai B, et al. Influence of lung CT changes in chronic obstructive pulmonary disease (COPD) on the human lung microbiome [J]. PLoS One, 2017, 12(7): e0180859.PubMedPubMedCentralCrossRef
57.
go back to reference Huang J T J, Cant E, Keir H R, et al. Endotyping Chronic Obstructive Pulmonary Disease, Bronchiectasis, and the “Chronic Obstructive Pulmonary Disease-Bronchiectasis Association” [J]. American Journal of Respiratory and Critical Care Medicine, 2022, 206(4): 417–426.PubMedCrossRef Huang J T J, Cant E, Keir H R, et al. Endotyping Chronic Obstructive Pulmonary Disease, Bronchiectasis, and the “Chronic Obstructive Pulmonary Disease-Bronchiectasis Association” [J]. American Journal of Respiratory and Critical Care Medicine, 2022, 206(4): 417–426.PubMedCrossRef
58.
go back to reference Ni Y, Shi G, Yu Y, et al. Clinical characteristics of patients with chronic obstructive pulmonary disease with comorbid bronchiectasis: a systemic review and meta-analysis [J]. Int J Chron Obstruct Pulmon Dis, 2015, 10: 1465–1475.PubMedPubMedCentralCrossRef Ni Y, Shi G, Yu Y, et al. Clinical characteristics of patients with chronic obstructive pulmonary disease with comorbid bronchiectasis: a systemic review and meta-analysis [J]. Int J Chron Obstruct Pulmon Dis, 2015, 10: 1465–1475.PubMedPubMedCentralCrossRef
59.
go back to reference Short B, Carson S, Devlin A C, et al. Non-typeable Haemophilus influenzae chronic colonization in chronic obstructive pulmonary disease (COPD) [J]. Crit Rev Microbiol, 2021, 47(2): 192–205.PubMedCrossRef Short B, Carson S, Devlin A C, et al. Non-typeable Haemophilus influenzae chronic colonization in chronic obstructive pulmonary disease (COPD) [J]. Crit Rev Microbiol, 2021, 47(2): 192–205.PubMedCrossRef
60.
go back to reference Jalalvand F, Riesbeck K. Haemophilus influenzae: recent advances in the understanding of molecular pathogenesis and polymicrobial infections [J]. Curr Opin Infect Dis, 2014, 27(3): 268–274.PubMedCrossRef Jalalvand F, Riesbeck K. Haemophilus influenzae: recent advances in the understanding of molecular pathogenesis and polymicrobial infections [J]. Curr Opin Infect Dis, 2014, 27(3): 268–274.PubMedCrossRef
61.
go back to reference Li L, Mac Aogáin M, Xu T, et al. Neisseria species as pathobionts in bronchiectasis [J]. Cell Host Microbe, 2022, 30(9). Li L, Mac Aogáin M, Xu T, et al. Neisseria species as pathobionts in bronchiectasis [J]. Cell Host Microbe, 2022, 30(9).
62.
go back to reference Van Der Bruggen T, Kolecka A, Theelen B, et al. Cutaneotrichosporon (Cryptococcus) cyanovorans, a basidiomycetous yeast, isolated from the airways of cystic fibrosis patients [J]. Med Mycol Case Rep, 2018, 22: 18–20.PubMedPubMedCentralCrossRef Van Der Bruggen T, Kolecka A, Theelen B, et al. Cutaneotrichosporon (Cryptococcus) cyanovorans, a basidiomycetous yeast, isolated from the airways of cystic fibrosis patients [J]. Med Mycol Case Rep, 2018, 22: 18–20.PubMedPubMedCentralCrossRef
63.
go back to reference Ranjan R, Rani A, Metwally A, et al. Analysis of the microbiome: advantages of whole genome shotgun versus 16S amplicon sequencing [J]. Biochem Biophys Res Commun, 2016, 469(4): 967–977.PubMedCrossRef Ranjan R, Rani A, Metwally A, et al. Analysis of the microbiome: advantages of whole genome shotgun versus 16S amplicon sequencing [J]. Biochem Biophys Res Commun, 2016, 469(4): 967–977.PubMedCrossRef
Metadata
Title
Respiratory microbiota and radiomics features in the stable COPD patients
Authors
Rong Wang
Chunrong Huang
Wenjie Yang
Cui Wang
Ping Wang
Leixin Guo
Jin Cao
Lin Huang
Hejie Song
Chenhong Zhang
Yunhui Zhang
Guochao Shi
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2023
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/s12931-023-02434-1

Other articles of this Issue 1/2023

Respiratory Research 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.